Innovent Biologics
Latest round
- Series E
Last raised
- Apr 2018
Total raised
- $545M
Investors
- 17
About Innovent Biologics
Established in 2011 and based in Suzhou, China, Innovent Biologics, Inc. is a biopharmaceutical company that engages in the development, manufacturing, and commercialization of new drugs for cancers. In October 2018, it was listed on the Hong Kong Stock Exchange under the number 01801. In December 2024, Innovent Biologics, Inc. It has multiple branches in Suzhou, Shanghai, Beijing, and overseas USA and Europe. Innovent Biologics, Inc. provides 35 monoclonal antibody drugs for cancer, immunity, and metabolic disease. It has eight products that were approved for marketing, and its product trademarks include TYVYT®, BYVASDA®, SULINNO®, HALPRYZA®, EMAZYRE®, and CYRAMZA®. It has 3 drugs in the NMPA review phase, 5 drugs are in the three-phase clinical trials, and the other 19 new drugs are in clinical research and development. Innovent Biologics, Inc. plans to promote lung cancer drugs IBI-351 (KRASG12C) and IBI-344 (ROS1/TRK) clinical registration and submit a new drug application (NDA) by the end of 2023. ADC molecular drugs will enter into the first phase of clinical trials. Besides, it also focuses on the fields of cardiovascular and metabolic, autoimmune, and ophthalmology. And obesity diabetes drug IBI-362, Tao drug IBI-311 will be in the third phase of registration clinical, and gout drug IBI-128 will be in the third phase of clinical trials by the end of 2023.
Who invested in Innovent Biologics
17 investors across 6 rounds
See all investors in Innovent Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Innovent Biologics
Who invested in Innovent Biologics?
Innovent Biologics has 17 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innovent Biologics raised?
Innovent Biologics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Innovent Biologics last raise money?
Innovent Biologics's most recent round on record is a Series E, in Apr 2018.
What does Innovent Biologics do?
Established in 2011 and based in Suzhou, China, Innovent Biologics, Inc.
Where is Innovent Biologics headquartered?
Innovent Biologics is headquartered in Suzhou, China.
Which VCs invest in companies like Innovent Biologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Innovent Biologics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series E
Raising like Innovent Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.